Merit Medical Systems Inc (MMSI) Stock
Key stats
- Market cap
- $5.28B
- Price / Earnings ratio
- 32.9x
- EPS (TTM)
- $2.69
- Volume
- Loading
- 52-week high
- $94.85
- 52-week low
- $59.74
Source: third-party data provider, as of November 13, 2026
Compare with MMSI
Recent news
Merit Medical Systems Q3 Earnings Call Highlights
Merit Medical Systems Q3 Earnings Call Highlights
MMSI
Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates
Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates
MMSI
Merit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say
Merit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say
MMSI
Cancer Stocks to Consider as Oncology Innovation Accelerates
Cancer Stocks to Consider as Oncology Innovation Accelerates
MMSINews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.29
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- 0.23
- MACD histogram
- -0.38
- SMA 50
- $88.13
- Price below SMA 50
- EMA 50
- $87.77
- Price above EMA 50
- SMA 200
- $77.16
- Price above SMA 200
- EMA 200
- $81.25
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.91 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Merit Medical Systems Q3 Earnings Call Highlights
Merit Medical Systems Q3 Earnings Call Highlights
MMSIMerit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates
Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates
MMSIMerit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say
Merit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say
MMSICancer Stocks to Consider as Oncology Innovation Accelerates
Cancer Stocks to Consider as Oncology Innovation Accelerates
MMSI
HSIC or MMSI: Which Is the Better Value Stock Right Now?
HSIC or MMSI: Which Is the Better Value Stock Right Now?
MMSI
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
MMSI
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
MMSI
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
MMSINews tone: automated (AI) classification of the article's content, not a price prediction.
About Merit Medical Systems Inc
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 1967 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 1979 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 1961 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 1973 |
| Mr. Neil W. Peterson | Senior Advisor | 1966 |
| Ms. Sarah Comstock | Vice President of Global Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.29
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- 0.23
- MACD histogram
- -0.38
- SMA 50
- $88.13
- Price below SMA 50
- EMA 50
- $87.77
- Price above EMA 50
- SMA 200
- $77.16
- Price above SMA 200
- EMA 200
- $81.25
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $90.00
- Average
- $104.83
- High
- $121.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.6 | +1.1 | ||||||||||
| 2022 | -13.1 | +16.5 | +2.2 | -8.9 | -2.4 | -11.3 | +4.6 | -1.3 | -3.6 | +18.7 | +4.3 | -2.6 |
| 2023 | +2.5 | -1.9 | +7.0 | +9.8 | +0.3 | +0.9 | -9.5 | -11.9 | +5.7 | +2.2 | +0.7 | +4.5 |
| 2024 | +2.5 | -4.8 | -0.7 | -1.4 | +5.9 | +4.6 | -0.4 | +14.9 | +3.4 | +1.1 | +5.2 | -7.7 |
| 2025 | +13.3 | -4.9 | +2.6 | -10.4 | +2.0 | -0.2 | -9.7 | +6.8 | -8.2 | +6.7 | -0.9 | +2.0 |
| 2026 | -6.2 | -5.4 | -9.9 | -0.1 | +1.7 | +11.7 | +22.4 | +6.0 | -4.9 | +0.1 | +4.5 |
